Atrial fibrillation (AFib) does not directly trigger ventricular tachycardia (VT) in most cases, but it significantly raises the risk. People hospitalized with AFib are four times more likely to experience ventricular arrhythmias or cardiac arrest compared to those without AFib. Even after accounting for other health conditions, AFib patients carry roughly a 35% higher risk of developing VT or a related ventricular rhythm problem than the general population.
The relationship between these two arrhythmias is indirect but real. AFib creates several conditions in the heart that can set the stage for dangerous ventricular rhythms over time.
How AFib Sets the Stage for Ventricular Arrhythmias
AFib doesn’t usually flip a switch that immediately starts VT. Instead, it works through a chain of effects that gradually make the ventricles more vulnerable. The most important of these is the sustained rapid heart rate that poorly controlled AFib produces. When the ventricles beat too fast for too long, the heart muscle itself begins to change. This condition, called tachycardia-induced cardiomyopathy, is in fact the most common consequence of AFib with a rapid ventricular response.
At the cellular level, prolonged fast rates cause heart muscle cells to stretch and die off. The internal scaffolding of the heart wall breaks down, the ventricles dilate, and the heart’s pumping ability deteriorates. These structural changes also alter the electrical behavior of individual heart cells: the electrical signals that coordinate each heartbeat become weaker and last longer than they should. Calcium channels, which play a central role in triggering each contraction, become less dense and less functional. All of these changes create the kind of unstable electrical environment where VT can start.
AFib also ramps up the sympathetic nervous system, the body’s “fight or flight” wiring. This hyperactivation increases calcium leakage inside heart cells, which can trigger abnormal electrical impulses called delayed afterdepolarizations. These rogue signals are a well-recognized trigger for ventricular arrhythmias. Over time, the nerves supplying the heart physically remodel in response to persistent AFib, creating a feedback loop that makes both atrial and ventricular rhythm problems harder to control.
The Special Danger of Accessory Pathways
There is one scenario where AFib can lead directly and rapidly to a life-threatening ventricular rhythm. In people with Wolff-Parkinson-White (WPW) syndrome, an extra electrical connection exists between the atria and ventricles. Normally, the heart’s main electrical gateway (the AV node) acts as a speed limiter, preventing too many atrial impulses from reaching the ventricles. An accessory pathway bypasses that limiter entirely.
When someone with WPW develops AFib, the chaotic atrial impulses can conduct straight to the ventricles at extremely high rates. If the accessory pathway has a short recovery time between beats (a short refractory period), the ventricles may be driven so fast that the rhythm degenerates into ventricular fibrillation, which is cardiac arrest. Research shows that WPW patients who develop spontaneous AFib tend to have accessory pathways with shorter refractory periods, meaning their ventricles are especially vulnerable to being overwhelmed. This is why AFib in someone with a known accessory pathway is treated as a medical emergency.
Medications That Treat AFib Can Trigger VT
One of the more counterintuitive risks is that the very drugs used to treat AFib can sometimes provoke ventricular tachycardia. This is called proarrhythmia, and it occurs in up to 5% of patients taking certain antiarrhythmic medications. The drugs most associated with this risk fall into two broad categories: sodium channel blockers (like flecainide and propafenone) and potassium channel blockers (like sotalol and dofetilide).
These medications work by altering how electrical signals move through the heart, which is exactly what makes them effective against AFib but also what makes them capable of creating new rhythm problems. The specific type of VT they most often trigger is called torsades de pointes, a distinctive pattern where the heart’s electrical axis appears to twist around the baseline on an ECG. The risk varies between individual drugs, even within the same class, which is why many of these medications are started in a hospital setting where heart rhythm can be monitored.
When AFib Mimics Ventricular Tachycardia
Not every wide, fast rhythm on a heart monitor is truly VT. AFib can produce beats that look remarkably like ventricular tachycardia on an ECG, a situation known as AFib with aberrant conduction. This happens when one of the heart’s electrical highways (the bundle branches) hasn’t fully recovered from the previous beat and temporarily fails to conduct. The resulting heartbeat takes a detour through the muscle itself, producing a wide, abnormal-looking complex on the ECG that can be mistaken for VT.
A classic example is the Ashman phenomenon. This occurs when a relatively long pause between beats is followed by a short interval. The long pause extends the recovery time of one bundle branch (usually the right one), and when the next beat arrives early, that branch can’t conduct. The result is one or more wide beats with a right bundle branch block pattern. A telltale clue is that the initial deflection of the wide beat looks normal, because the impulse still originates above the ventricles. Ashman beats can appear in clusters, sometimes mimicking a run of VT.
Distinguishing true VT from AFib with aberrancy matters enormously because the treatments are different. Clinicians use several ECG features to tell them apart, including whether the atria and ventricles are beating independently (a hallmark of VT), the width and shape of the QRS complex, and the direction of the electrical axis. Structured diagnostic tools like the Brugada algorithm help standardize this process. In one study where patients were referred for invasive testing to settle the diagnosis, every case that initially looked like VT turned out to be a supraventricular rhythm with aberrancy, including several cases of AFib.
Who Is Most at Risk
A large population-based study tracking patients over a median of 5.4 years found that the annual incidence of ventricular arrhythmias and cardiac arrest was 2.23% in AFib patients compared to 0.56% in people without AFib. Importantly, the study also showed that the risk of cardiac arrest in AFib patients was statistically mediated by ventricular arrhythmias, meaning VT and ventricular fibrillation appear to be a key link in how AFib leads to cardiac arrest.
Several factors raise the risk further. Heart failure, whether it existed before AFib or developed as a result of it, makes the ventricles more electrically unstable. Poorly controlled ventricular rate over months or years compounds structural damage. The use of proarrhythmic medications adds an iatrogenic layer of risk. And the presence of an accessory pathway, even one that has never caused symptoms, turns AFib from a manageable nuisance into a potentially fatal event.
The practical takeaway is that while AFib sits in the atria and VT originates in the ventricles, these two rhythms are not independent problems. AFib reshapes the heart’s structure, disrupts its electrical stability, activates its stress responses, and sometimes delivers impulses to the ventricles faster than they can safely handle. Each of these mechanisms creates a pathway from one arrhythmia to the other.